Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $66.51 down -3.00% from its previous closing price of $68.57. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 0.94 million shares were traded. SLNO stock price reached its highest trading level at $68.7 during the session, while it also had its lowest trading level at $66.285.
Ratios:
For a deeper understanding of Soleno Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.01 and its Current Ratio is at 15.13. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $123.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 3534674176 and an Enterprise Value of 3410081280. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.24 while its Price-to-Book (P/B) ratio in mrq is 13.97. Its current Enterprise Value per Revenue stands at 104.421 whereas that against EBITDA is -18.501.
Stock Price History:
The Beta on a monthly basis for SLNO is -2.72, which has changed by 0.3562398 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -18.44%, while the 200-Day Moving Average is calculated to be 4.48%.
Shares Statistics:
For the past three months, SLNO has traded an average of 1.33M shares per day and 2097060 over the past ten days. A total of 50.44M shares are outstanding, with a floating share count of 45.97M. Insiders hold about 13.50% of the company’s shares, while institutions hold 96.48% stake in the company. Shares short for SLNO as of 1753920000 were 6040860 with a Short Ratio of 4.56, compared to 1751241600 on 5353951. Therefore, it implies a Short% of Shares Outstanding of 6040860 and a Short% of Float of 13.089999999999998.
Earnings Estimates
The dynamic stock of Soleno Therapeutics Inc (SLNO) is currently being evaluated by a team of 10.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.2, with high estimates of $0.62 and low estimates of -$0.41.
Analysts are recommending an EPS of between $0.24 and -$1.69 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is $3.01, with 10.0 analysts recommending between $5.56 and $1.01.
Revenue Estimates
For the next quarter, 10 analysts are estimating revenue of $61.6M. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $40.2M. Based on 10 analysts’ estimates, the company’s revenue will be $397.47M in the next fiscal year. The high estimate is $551.75M and the low estimate is $252.18M.
